+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tenofovir Disoproxil Fumarate Tablets Market by Dosage Strength (150 Mg, 300 Mg), Product Type (Branded, Generic), Treatment Regimen, Distribution Channel, Indication, Packaging Type - Global Forecast 2025-2030- Product Image
Tenofovir Disoproxil Fumarate Tablets Market by Dosage Strength (150 Mg, 300 Mg), Product Type (Branded, Generic), Treatment Regimen, Distribution Channel, Indication, Packaging Type - Global Forecast 2025-2030- Product Image
Sale

Tenofovir Disoproxil Fumarate Tablets Market by Dosage Strength (150 Mg, 300 Mg), Product Type (Branded, Generic), Treatment Regimen, Distribution Channel, Indication, Packaging Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6080650
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Tenofovir Disoproxil Fumarate tablets have emerged as a critical therapy in the global fight against HIV and Hepatitis B, offering proven efficacy while increasing patient access through the rapid rise of generics. Stakeholders in the antiviral market face continuing change driven by technology, policy, and supply chain forces shaping future strategies.

Market Snapshot: Tenofovir Disoproxil Fumarate Tablets

The Tenofovir Disoproxil Fumarate (TDF) tablets market is marked by accelerated growth, resulting from expanding generic availability, evolving procurement policies, and robust regulatory endorsements. With original patents expiring, generics now play a decisive role in broadening treatment reach and supporting health systems globally. Advances in patient-centric drug delivery and digital adherence platforms are further transforming distribution and therapeutic outcomes, while shifting global guidelines continue to influence prescriber and payer adoption patterns.

Scope & Segmentation

The report provides a comprehensive assessment of the TDF tablets sector, covering multiple dimensions key for senior decision-makers:

  • Dosage Strengths: 150 mg for specific maintenance protocols and 300 mg, widely adopted for both prevention and active treatment.
  • Product Types: Branded and generic formulations, each impacting adoption rates and reimbursement landscapes.
  • Treatment Regimens: Use in combination therapy to enhance viral suppression, as well as in monotherapy aligned to patient needs.
  • Distribution Channels: Hospital-based dispensing, online pharmacy provision, and traditional retail pharmacy networks.
  • Indications: Applications include Hepatitis B treatment, HIV prophylaxis, and HIV active treatment.
  • Packaging Types: Bottles and strip packaging formats, each supporting shelf life and patient compliance.
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (including UK, Germany, France, Russia, Italy, Spain, and selected Middle Eastern and African markets), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Leading Companies: Major players include Gilead Sciences, Viatris, Teva, Cipla, Aurobindo Pharma, Hetero Drugs, Sun Pharma, Zydus Lifesciences, Lupin, and Emcure Pharmaceuticals.
  • Technology Use: Focus on nanoparticle encapsulation, extended-release matrices, and digital platforms supporting adherence.

Key Takeaways for Senior Decision-Makers

  • Growing generic competition is putting increased emphasis on operational efficiency and cost competitiveness for both established manufacturers and new entrants.
  • Adoption of advanced formulation techniques, such as nanoparticle encapsulation and extended-release, is driving improved patient experience and potentially differentiating products in mature markets.
  • Intensified collaboration with digital health vendors supports real-time adherence monitoring, particularly in regions with variable care continuity.
  • Dynamic regulatory environments worldwide enable faster market entry for generics through revised approval pathways, but also require ongoing monitoring for compliance.
  • Segmentation by region, product type, and packaging enables tailored strategies to optimize supply chain resilience and maximize therapeutic reach.
  • Patient advocacy and payers increasingly influence market deployment, necessitating transparent dialogue and outcome-based agreements.

Tariff Impact

Recent implementation of United States tariffs on pharmaceutical ingredients has increased the cost burden on TDF manufacturing, leading to supply chain adjustments that include dual-sourcing, contingency warehousing, and renegotiation of trade agreements. These measures aim to preserve affordability and continuous patient access. Downstream stakeholders—distributors, providers, and patient groups—are advocating for tariff exemptions to maintain medication flow, especially in regions heavily reliant on imports.

Methodology & Data Sources

This report draws on quantitative analysis from peer-reviewed literature, regulatory filings, and procurement databases, supplemented by qualitative interviews with clinicians, supply chain professionals, and procurement experts. A structured literature review supports and validates the research conclusions, while internal advisory panels review all findings for accuracy and practical relevance.

Why This Report Matters

  • Equips senior leaders with actionable intelligence to inform procurement, manufacturing, and commercialization strategies for TDF tablets in shifting regulatory and market environments.
  • Provides in-depth analysis of technological innovations, patient adherence platforms, and trade obstacles, enabling better investment and operational decisions.
  • Supports cross-functional alignment by clarifying segmentation drivers, regional adoption challenges, and emerging industry best practices.

Conclusion

Tenofovir Disoproxil Fumarate tablets remain central to contemporary antiviral therapy. By understanding the evolving segmentation, market dynamics, and strategic imperatives outlined, decision-makers are equipped to navigate complexity and accelerate therapeutic access for diverse populations.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growth of generic TDF tablets driving dramatic price reductions and increased accessibility
5.2. Advancements in fixed-dose combination therapies including tenofovir disoproxil fumarate for simplified HIV treatment
5.3. Rising investments in R&D for novel tenofovir formulations targeting improved renal safety profiles
5.4. Regulatory approvals for new tenofovir disoproxil fumarate generics accelerating market expansion in emerging economies
5.5. Increasing adoption of TDF-based pre-exposure prophylaxis programs boosting demand across high-risk populations
5.6. Strategic partnerships between biotech firms and CROs enhancing clinical pipeline for tenofovir analog development
5.7. Market shift towards multi-year procurement contracts for TDF tablets to secure long-term supply stability
5.8. Surge in competitive marketing campaigns emphasizing TDF tablet efficacy in HBV co-infection management
5.9. Emergence of local manufacturing hubs reducing import reliance and optimizing tenofovir distribution logistics
5.10. Impact of raw material price volatility on tenofovir disoproxil fumarate tablet production costs and margins
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tenofovir Disoproxil Fumarate Tablets Market, by Dosage Strength
8.1. Introduction
8.2. 150 Mg
8.3. 300 Mg
9. Tenofovir Disoproxil Fumarate Tablets Market, by Product Type
9.1. Introduction
9.2. Branded
9.3. Generic
10. Tenofovir Disoproxil Fumarate Tablets Market, by Treatment Regimen
10.1. Introduction
10.2. Combination Therapy
10.3. Monotherapy
11. Tenofovir Disoproxil Fumarate Tablets Market, by Distribution Channel
11.1. Introduction
11.2. Hospital
11.3. Online
11.4. Pharmacy
12. Tenofovir Disoproxil Fumarate Tablets Market, by Indication
12.1. Introduction
12.2. Hepatitis B Treatment
12.3. Hiv Prophylaxis
12.4. Hiv Treatment
13. Tenofovir Disoproxil Fumarate Tablets Market, by Packaging Type
13.1. Introduction
13.2. Bottle
13.3. Strip
14. Americas Tenofovir Disoproxil Fumarate Tablets Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Tenofovir Disoproxil Fumarate Tablets Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Tenofovir Disoproxil Fumarate Tablets Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Gilead Sciences, Inc.
17.3.2. Viatris Inc.
17.3.3. Teva Pharmaceutical Industries Ltd.
17.3.4. Cipla Limited
17.3.5. Aurobindo Pharma Limited
17.3.6. Hetero Drugs Limited
17.3.7. Sun Pharmaceutical Industries Limited
17.3.8. Zydus Lifesciences Limited
17.3.9. Lupin Limited
17.3.10. Emcure Pharmaceuticals Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET: RESEARCHAI
FIGURE 28. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET: RESEARCHSTATISTICS
FIGURE 29. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET: RESEARCHCONTACTS
FIGURE 30. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY 150 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY 150 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY 300 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY 300 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HEPATITIS B TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HEPATITIS B TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HIV PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HIV PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HIV TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY HIV TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY BOTTLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY BOTTLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STRIP, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STRIP, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 77. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 78. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 79. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 82. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 83. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 88. CANADA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 89. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 90. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 91. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 94. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 95. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 100. MEXICO TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 101. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 102. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 113. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 114. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 140. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 151. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 152. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 153. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 154. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 155. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 156. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 157. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 162. GERMANY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 163. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 164. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 165. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 168. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 169. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 174. FRANCE TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 175. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 176. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 187. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 188. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 189. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 190. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 191. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 192. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 193. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 196. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 197. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 198. ITALY TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 199. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 200. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 201. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 204. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 205. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 210. SPAIN TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 224. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 236. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 238. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 247. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 248. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 249. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 252. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 253. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 258. DENMARK TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 259. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 260. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 261. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 271. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 272. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 273. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 276. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 277. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 282. QATAR TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 283. FINLAND TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 284. FINLAND TENOFOVIR DISOPROXIL FUMARATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-203

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Tenofovir Disoproxil Fumarate Tablets market report include:
  • Gilead Sciences, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Hetero Drugs Limited
  • Sun Pharmaceutical Industries Limited
  • Zydus Lifesciences Limited
  • Lupin Limited
  • Emcure Pharmaceuticals Limited

Related Topics

Related Reports

Tenofovir Disoproxil Fumarate (CAS 202238-50-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Tenofovir Disoproxil Fumarate (CAS 202238-50-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Tenofovir Disoproxil Global Market Report 2025 - Product Image

Tenofovir Disoproxil Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
HIV Drugs Market Report 2025 - Product Image

HIV Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Lamivudine Drugs Market by Formulation (Injection, Oral Solution, Oral Tablet), Product Type (Combination Therapy, Single Therapy), Dosage Strength, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Lamivudine Drugs Market by Formulation (Injection, Oral Solution, Oral Tablet), Product Type (Combination Therapy, Single Therapy), Dosage Strength, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode Of Administration, Patient Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode Of Administration, Patient Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.